[E-Daily Reporter Park Jung-Soo ] INNOGENE Co., Ltd.(344860), a company developing anti-aging solutions such as hair loss treatments and skin regeneration, announced on the 6th that it has signed a Memorandum of Understanding (MOU) with Humic to conduct joint research and development in the anti-aging bio and healthcare sectors. This agreement was established to jointly develop functional bio-materials and anti-aging solutions based on the research capabilities of both companies and to build a foundation for commercialization.
Under the agreement, the two companies will jointly develop functional biomaterials and raw materials based on anti-aging technology and conduct preclinical studies on the efficacy, safety, and biological mechanisms of action of the developed materials. They also plan to collaborate on the development of technologies for analyzing anti-aging biomarkers and verifying efficacy, as well as establishing a testing and evaluation system to support domestic and international regulatory approvals.
INNOGENE Co., Ltd. has been conducting research on functional products and biomaterials in the fields of hair loss and scalp care, and has recently expanded its business into distribution to hospitals and clinics as well as the digital healthcare sector, developing functional cosmetics, medical devices, and digital diagnostic platforms.
Humic is a CRO (Contract Research Organization) specializing in non-clinical trials using humanized mice. Leveraging its expertise in non-clinical evaluation for anti-aging and novel biopharmaceuticals, the company has established various disease models and efficacy validation systems to support the R&D efforts of domestic and international biotech firms.
Through this agreement, the two companies plan to establish a collaborative framework spanning the development of functional materials, efficacy verification, safety assessment, biomarker-based research, and product commercialization. Through this partnership, they aim to develop next-generation anti-aging solutions that integrate anti-aging technology with bio- and healthcare technologies and to expand into the global market.
An INNOGENE Co., Ltd. official stated, “This agreement will serve as an opportunity to combine the expertise and research capabilities of both companies to lay a new foundation for growth in the anti-aging field,” adding, “We will strengthen our competitiveness in the global biotech and healthcare market through continuous research, development, and collaboration.”